The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

BACKGROUND: Pancreatic cancer continues to have a 5-year survival of less than 5%. Therefore, more effective therapies are necessary to improve prognosis in this disease. Angiogenesis is required for tumor growth, and subsequently, mediators of angiogenesis are attractive targets for therapy. Vascul...

Descripción completa

Detalles Bibliográficos
Autores principales: Dineen, Sean P, Sullivan, Laura A, Beck, Adam W, Miller, Andrew F, Carbon, Juliet G, Mamluk, Roni, Wong, Henry, Brekken, Rolf A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627916/
https://www.ncbi.nlm.nih.gov/pubmed/19038046
http://dx.doi.org/10.1186/1471-2407-8-352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627916/
https://www.ncbi.nlm.nih.gov/pubmed/19038046
http://dx.doi.org/10.1186/1471-2407-8-352

Ejemplares similares